<DOC>
	<DOCNO>NCT00873561</DOCNO>
	<brief_summary>This study design evaluate efficacy multiple dose investigational drug , NBI-6024 , adult ( 18 35 year age ) adolescent ( 10 17 year age ) patient new onset type 1 diabetes mellitus , endogenous insulin production . A total 188 patient enrol study . The study divide three period : screening , treatment ( comprise induction phase maintenance phase ) , follow-up . NBI-6024 generally well tolerate exhibit benign safety profile , significant safety issue NBI-6024 treatment . In summary , NBI-6024 demonstrate statistically significant efficacy compare placebo .</brief_summary>
	<brief_title>A Study Evaluate NBI-6024 Adult Adolescent Patients With New Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>This Phase II , multicenter ( international ) , randomize , double-blind , placebo-controlled , parallel , dose-ranging study evaluate efficacy multiple dos alter peptide ligand , NBI-6024 , adult ( 18 35 year age ) adolescent ( 10 17 year age ) patient new onset type 1 diabetes mellitus . Study drug administer subcutaneously total 26 time 24-month period . The first three dos administer every 2 week ( induction phase ) ; subsequent dosing occur monthly ( maintenance phase ) . Patients return study center receive study drug efficacy safety assessment collect . The primary efficacy endpoint 2-hour peak C-peptide Month 24 . Other secondary analysis include AUC C-peptide , prescribe insulin usage , AUC blood glucose , HbA1c , hypoglycemic event , hyperglycemic event .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female age 12 35 year , inclusive ( change age 10 35 year , inclusive , Amendment 2 ) If female childbearing potential , patient must use acceptable method birth control prior 30 day post study Adult ( great equal 18 year ) female patient childbearing potential must 2 year postmenopausal , hysterectomy tubal ligation Were newly diagnose type 1 diabetes mellitus Presence one following : AntiICA512 antibody AntiGAD antibody Antiinsulin antibody , provide patient insulin therapy great 1 week Body mass index ( BMI ) &lt; 28 kg/m2 Stimulated serum Cpeptide peak level 0.4 pmol/mL 3.0 pmol/mL , inclusive , time screen Laboratory 12lead electrocardiogram ( ECG ) result within normal range , abnormal , consider investigator non clinically significant safety well patient purpose study Use exclude medication/therapy include follow : Steroids Oral hypoglycemic agent Chemotherapy radiation Immunosupressants Nicotinamide &gt; 100 mg per day Any drug contain sibutramine Female patient positive pregnancy test lactate Adult patient body weight &lt; 45 kg ; adolescent patient body weight &lt; 30 kg ; 10 11yearold patient body weight &lt; 25 kg History cancer exist actively manage cancer History severe anaphylactic allergic reaction Patients suffer active skin infection would prevent subcutaneous injection Positive test HIV antigens , hepatitis B surface antigen , hepatitis C antibodies History alcohol substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 1</keyword>
	<keyword>adult</keyword>
	<keyword>adolescent</keyword>
	<keyword>new onset</keyword>
</DOC>